359 Negative genetic neonatal screening for cystic fibrosis caused by compound heterozygosity for two large CFTR rearrangements  by Guittard, C. et al.
S88 13. Screening/Diagnosis
359 Negative genetic neonatal screening for cystic ﬁbrosis caused
by compound heterozygosity for two large CFTR rearrangements
C. Guittard1, J.P. Altieri1, C. Templin1, N. Stremler2, C. Beroud1, M. Claustres1,
M. des Georges1. 1Laboratoire de Ge´ne´tique Mole´culaire, CHU, Montpellier,
France; 2CRCM, CHU-Timone, Marseille, France
Newborn screening programs for CF are applied in France for almost 800,000
newborns each year, based on IRT assay from dried blood spots, followed, when
IRT is positive, by testing for the 30 most common CFTR mutations. Infants with
positive sweat test are further investigated for CFTR point mutations, which usually
results in the identiﬁcation of two mutant alleles. We experienced a case of CF
with meconium ileus positive but with no mutation after sequencing of CFTR
coding/ﬂanking regions. By using a semi-quantitative ﬂuorescent PCR assay, we
detected a deletion of exons 2, 18, 19, 20 previously named 2, 16, 17a, 17b.
Segregation analysis and extensive study of the CFTR locus revealed that the
neonate carried the previously described [c.54–5811_c.164+2186del8108ins182],
inherited from his father, and a novel [c.2908+1085_c.3367+260del7201] rearrange-
ment, inherited from his South Korean mother, involving exons previously reported
in another deletion [c.2909–636_c.3368+1611del6965ins32]. In our knowledge, this
is the ﬁrst case of compound heterozygosity for two CFTR large rearrangements.
This study emphazises on several points: (1) CF can be found in virtually every
ethnic group, including non-Caucasian Asiatic populations; (2) CF can be caused
by the inheritance of two heterozygous large rearrangements; (3) The same exons
can be involved in different rearrangements; (4) Using the original CFTR gene data
rather than the international nomenclature for gene exons and mutations may lead
to misdiagnosis; (5) Sequencing the breakpoint junction is recommended because
misdiagnosis could result from the use of rapid PCR assays designed to only test
junctions of rearrangements.
360 Pulmonary and nutritional outcomes in children with cystic ﬁbrosis
(CF) detected through neonatal screening and by symptoms in
Argentina
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Hospital La Plata, La Plata, Buenos Aires, Argentina
Screening for CF in the newborn period has been established in many regions of the
world. Previous studies have shown that the early treatment in the newborn period
results in improved nutritional and clinical outcomes.
Objective: To compare pulmonary and nutritional status in children with CF detected
through neonatal screening and by symptoms in follow-up at our center.
Methods: Cross sectional study. We assessed two groups of patients matched by age,
sex and genotype; a group A (GA) detected by neonatal screening, and a group B (GB)
by symptoms; both diagnosed by sweat test. Immunoreactive trypsinogen analysis (IRT)
was used for neonatal screening (cut-off value 70 ug/ml). We evaluated age at diagnosis,
age of ﬁrst isolation of Pseudomonas aeruginosa (Pa), number of hospital admissions
(A). Also we assessed Z score for weight/age (W/A) at ﬁrst visit in our center, and
Z score of Body Mass Index (BMI), Z score for height/age (H/A), score Shwachman
Brasﬁeld (S/B) and FEV1 at last visit. Chi2 and Wilcoxon tests were performed to
compare the results.
Results: 21 children with CF were enrolled for each group (12 boys and 9 girls).
Eleven patients for each group had mutations class II in both alleles.
Conclusions: Early diagnosis and therapeutic management of CF detected through
neonatal screening result in signiﬁcantly enhanced in nutritional and pulmonary status.
In developing countries the carrying out of screening programs must be considered.
n X age
(years)
Age at
diagnosis
(years)*
z
W/A*
z BMI z H/A* S/B* FEV1
(%)
A* Age 1st Pa
GA 21 4.2 0.16 −0.66 0.19 0.1 81.2 99 1.42 1.11
GB 21 4.4 1.03 −2.23 0.17 −0.68 72.7 81 3.28 1.67
*p< 0.05
361 Pulmonary function in infants with cystic ﬁbrosis (CF) detected
through neonatal screening and by symptoms in Argentina
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La Plata, Buenos Aires, Argentina
Rationale: The most of the patients with Cystic Fibrosis (CF) is detected through
neonatal screening or by symptoms. Lung disease in CF is at the beginning a disease
mainly of the small airways. Although infants with CF have normal lung at birth,
respiratory dysfunction often develops in the ﬁrst year.
Objective: To compare pulmonary function in children younger than 24 months
detected through neonatal screening and by symptoms in follow-up at our center.
Methods: Cross sectional study. We measured: Functional Residual Capac-
ity (FRC), Airway Resistance (Raw), and Maximal Expiratory Flow at FRC
(V’maxFRC) with Jaeger® equipment. We compared two groups of patients with
similar age: group A detected by neonatal screening (GA), and group B by
symptoms (GB), both diagnosed by sweat test. For neonatal screening we used
immunoreactive trypsinogen (IRT) in dried blood spots (cut-off value: 70 ug/ml).
Student’s t-test was performed to compare the means of the indicators using the
SSPS software 9.0.
Results: 20 infants with CF were enrolled (8 in GA and 12 in GB) with a mean
age of 15.9±8 months, height 73±9 cm, z score for weight/age −1.2 and height/age
−1.3. Mean V’maxFRC was 173.4±96ml/s and its z score −1.34±1.6. FRC was
263.9±135ml and Raw 1.67±1.2. Fourteen patients ﬁnished all measurements
(6 GA and 8 GB).
Conclusion: Our infants with Cystic Fibrosis detected through neonatal screening
had higher V’maxFRC and lower FRC and Raw than non-screened group. These
ﬁndings should be taking into account when CF programs are considered.
n Height (cm) V’maxFRC (ml/s* z V’maxFRC* FRC (ml) Raw
GA 6 68.1 229 −0.06 191 0.71
GB 8 69.7 104 −2.19 224 1.70
*p< 0.05
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Aim: To evaluate the analytical characteristics of the Dynabio® PAP ELISA.
Methods: Analytical precision, linearity, lower limit of detection and potential
interferences were determined according to Clinical & Laboratory Standards In-
stitute guidelines EP5-A, EP6-A, EP7-A, EP9-A2 using recombinant human PAP
(rhPAP) measured with the Dynabio® PAP ELISA (Marseille, France) according
to manufacturer’s speciﬁcations.
Results: Within-run precisions were 0.9% and 11.8% at 0.25 and 0.015mg/L
concentrations of rhPAP, respectively. The lower limit of detection was 0.015mg/L.
The reportable range was 0.03 to 0.125 mg/L when the data were analyzed as
optical density (OD) versus concentration. A double reciprocal plot of optical
density versus rhPAP concentration extended the assay linearity (0.015 to 0.25
mg/L). The equations of the line and correlation coefﬁcients were y = 7.7(x) + 0.220
and r = 0.985; y = 0.07(x) + 0.123 and r = 0.994 for OD versus concentration and
1/OD and 1/concentration analyses, respectively.
Conclusions: 1) The precision and lower limit of detection of the Dynabio®
PAP ELISA (Marseille, France) meet analytical expectations for newborn cystic
ﬁbrosis screening. 2) The reportable range of linear results is extended when double
reciprocal graphing of optical density versus rhPAP concentration is conducted.
